Flow cytometric analysis of human peripheral blood cells labeled with Anti-Human HLA-DR antibody at 1/200 dilution (1 μg) / (right panel) compared with a Mouse IgG2b, κ Isotype Control / (left panel). Goat Anti-Mouse IgG Alexa Fluor® 488 was used as the secondary antibody. Then cells were stained with CD19 - Brilliant Violet 421™ antibody separately. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | HLA-DR |
| Synonyms | HLA class II histocompatibility antigen, DR alpha chain; MHC class II antigen DRA; HLA-DRA1; HLA-DRA |
| Location | Cell membrane, Endoplasmic reticulum membrane |
| Accession | P01903 |
| Clone Number | TU36 |
| Antibody Type | Mouse mAb |
| Isotype | IgG2b,k |
| Isotype Control | S0B0618 |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | Human peripheral blood cells |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1:200 | Hu |
Background
HLA-DR is a subtype of the human leukocyte antigen (HLA) complex, specifically classified as a class II molecule, and is encoded by genes located on chromosome 6. It plays a crucial role in the immune system by presenting peptide antigens to CD4+ T cells, which subsequently trigger adaptive immune responses, including the activation of B cells and the production of antibodies. HLA-DR is primarily expressed on antigen-presenting cells such as macrophages, dendritic cells, and B cells, and its expression levels can indicate the degree of immune system activation. This molecule is also significant in clinical settings, as it is associated with various autoimmune diseases (e.g., rheumatoid arthritis linked to HLA-DR4) and is a key factor in determining the success of organ transplants. Additionally, HLA-DR has been studied in the context of cancer immunotherapy, where its expression on tumor cells can influence the effectiveness of immune-mediated tumor suppression.
Picture
Picture
FC
